Klingman & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Klingman & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Sell	384 -7	-2%	-$4.76K	0.01%	311
2026 Q1	$302K	Buy	391 +9	+2%	+$6.89K	0.01%	258
2025 Q4	$295K	Buy	+382	New	+$259K	0.01%	257
2025 Q3	–	Sell	-382	Closed	-$201K	–	335
2025 Q2	$201K	Buy	+382	New	+$213K	0.01%	310
2025 Q1	–	Sell	-291	Closed	-$207K	–	272
2024 Q4	$207K	Buy	291 +34	+13%	+$28.5K	0.01%	248
2024 Q3	$270K	Buy	257 +4	+2%	+$4.45K	0.02%	225
2024 Q2	$266K	Buy	253 +2	+0.8%	+$1.94K	0.02%	207
2024 Q1	$242K	Buy	251 +4	+2%	+$3.8K	0.02%	217
2023 Q4	$217K	Buy	247 +3	+1%	+$2.47K	0.02%	217
2023 Q3	$201K	Buy	+244	New	+$192K	0.02%	213

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Klingman & Associates's REGN Position: Q2 2026 in Review

Klingman & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 1.8% in Q2 2026, selling an estimated $4.76K and leaving 384 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #311.

Klingman & Associates first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $302K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Klingman & Associates held 384 shares of Regeneron Pharmaceuticals worth $239K as of Q2 2026.
Klingman & Associates sold 7 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.76K.
Regeneron Pharmaceuticals made up 0.01% of Klingman & Associates's portfolio in Q2 2026, its #311 holding.
Klingman & Associates first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
Klingman & Associates's Regeneron Pharmaceuticals position peaked at $302K in Q1 2026.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Klingman & Associates's 13F filing for Q2 2026, filed 29 Jul 2026.